Research & Publications
Dr. Heimer is also the Director of the Yale office of the Connecticut Emerging Infections Program. This Centers for Disease Control and Prevention-funded program is one of eleven programs nationwide that seek to assess, through population-based surveillance, the public health impact of emerging infectious diseases and to evaluate methods for their prevention and control in the community. The Yale program currently focuses on foodborne illnesses, and respiratory illnesses (influenza and RSV), tick borne diseases, and hospital acquired and related infections (including but not limited to C. difficile, antimicrobial resistant enterococci, S. aureus, and bloodstream candidemia).
In a second domain, Dr. Heimer's major research efforts include scientific investigations of the mortality and morbidity associated with illicit drug use. Areas of investigation include syringe exchange programs, HIV survival in syringes, hepatitis B vaccination, hepatitis C transmission risks, overdose prevention and resuscitation, and pharmacological treatment of opiate addiction. His research combines laboratory, operational, and ethnographic analyses to evaluate the effectiveness of intervention programs in preventing the negative medical consequences of injection drug use. Dr. Heimer is a member of Yale's Center for Interdisciplinary Research on AIDS and the CT Opioid Response Team established in 2016 by Governor Daniel Malloy.
Specialized Terms: Mortality and morbidity in relation to injection drug use; HIV and hepatitis C transmission; Evaluation of prevention and treatment for people who inject drugs
Extensive Research Description
Robert Heimer is Professor of Epidemiology at the Yale School of Public Health and of Pharmacology at Yale University School of Medicine. Dr. Heimer’s research provides health and prevention practitioners with information by examining consequences of drug abuse in the United States, Russia, and in other global contexts.
Current research and program evaluation efforts are funded by NIH, CDC, FDA, and the Gilead Foundation.
Acquired Immunodeficiency Syndrome; Epidemiology; Foodborne Diseases; Hepatitis C; Injections; Public Health; Russia; Vietnam; Global Health; HIV Infections
Public Health Interests
HIV/AIDS; Substance Use, Addiction; COVID-19